Previous close | 1.6800 |
Open | 1.6700 |
Bid | 1.7300 x 400 |
Ask | 1.7600 x 400 |
Day's range | 1.6600 - 1.7600 |
52-week range | 1.5500 - 8.6000 |
Volume | |
Avg. volume | 348,072 |
Market cap | 42.97M |
Beta (5Y monthly) | 0.30 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.4400 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.67 |
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance. These data will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor (PEComa) had gynecologic origins experienced efficacy and safety consistent with the overall study population. The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanc
Aadi Bioscience ( NASDAQ:AADI ) Full Year 2023 Results Key Financial Results Revenue: US$24.4m (up 60% from FY 2022...